EZH2 and leukemia: To determine whether CD82 expression in leukemia cells affects the amount of PTEN promoter-bound EZH2 or the trimethylation status of H3K27 in this region, we performed ChIP assays using anti-EZH2 or-H3K27me3 antibodies in EOL-1R and MOLM13 cells (Fig 3A and 3B).